Palatin Technologies (NYSEAMERICAN:PTN) received a $6.00 price objective from equities researchers at Canaccord Genuity in a research note issued to investors on Monday, November 13th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock.
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Palatin Technologies from a “buy” rating to a “strong sell” rating in a research note on Wednesday, November 1st. Roth Capital set a $2.00 price target on shares of Palatin Technologies and gave the company a “buy” rating in a research note on Sunday, October 29th.
Shares of Palatin Technologies (PTN) traded up $0.01 during trading on Monday, reaching $0.94. 1,480,000 shares of the company were exchanged, compared to its average volume of 1,790,000. Palatin Technologies has a 12-month low of $0.29 and a 12-month high of $1.05.
A hedge fund recently raised its stake in Palatin Technologies stock. Bank of New York Mellon Corp raised its holdings in shares of Palatin Technologies, Inc. (NYSEAMERICAN:PTN) by 500.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 151,473 shares of the biopharmaceutical company’s stock after buying an additional 126,236 shares during the period. Bank of New York Mellon Corp owned about 0.08% of Palatin Technologies worth $101,000 as of its most recent SEC filing.
ILLEGAL ACTIVITY NOTICE: “Palatin Technologies (NYSEAMERICAN:PTN) PT Set at $6.00 by Canaccord Genuity” was first reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/palatin-technologies-inc-ptn-given-a-6-00-price-target-at-canaccord-genuity/1781537.html.
About Palatin Technologies
Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.
Receive News & Ratings for Palatin Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies Inc. and related companies with our FREE daily email newsletter.